Early trial tests new Pill's power against tough cancers
Disease control
Completed
This early-phase study tested a new oral drug called RP-3500 (camonsertib) in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe and effective dose, check how the body processes the drug, and see if it could he…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC